Clotting Disorders

Clotting Disorders

A collection of features and news articles published in ASH Clinical News related to clotting disorders.

On location

DVT Increases Health-Care Burden and Mortality in Patients with Cancer

Patients with cancer and deep vein thrombosis (DVT) experience higher rates of hospitalization and mortality, are less frequently treated with thrombolysis, and experience gastrointestinal...

Apixaban Noninferior to Subcutaneous Dalteparin for Cancer-Associated VTE

Results from the CARAVAGGIO trial showed the direct oral anticoagulant apixaban was as effective as dalteparin, a type of low-molecular-weight heparin, in preventing recurrent...
WIB_icon

Twice-Daily Low-Dose Aspirin Improves Antiplatelet Response in Essential Thrombocythemia

Once-daily aspirin 75 to 100 mg is the current recommended antithrombotic regimen for patients with essential thrombocythemia (ET), but once-daily aspirin may not be...

FDA Grants Orphan Drug Designations to Avatrombopag and CLR 131

The FDA has granted orphan drug designations to two therapies for hematologic conditions. The oral thrombopoietin receptor agonist avatrombopag is indicated for the treatment of...

Metabolic Syndrome Predicts Risk of Recurrent VTE in Patients With Newly Diagnosed DVT

Patients with newly diagnosed deep vein thrombosis (DVT) who have components of metabolic syndrome – hypertension, hyperlipidemia, diabetes mellitus, or obesity – have a...
WIB_icon

Peripherally Inserted Central Catheters Sharply Increase Risk of Childhood VTE Events

In children who received central venous catheters, peripherally inserted central catheters (PICCs) appear to be associated with a higher risk of venous thromboembolism (VTE),...

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...

Updates on ASH Clinical Practice Guidelines in Development

In 2019, the American Society of Hematology (ASH) continued its efforts to develop and publish evidence-based clinical practice guidelines to help practicing hematologists and...

Early Removal of Central Venous Catheters Does Not Increase Risk of PE

Among patients with a hematologic malignancy and central venous catheter–associated upper extremity deep vein thrombosis (UEDVT), removal of catheters within 48 hours did not...
How I Treat In Brief

How I Treat in Brief: Venous Thromboembolism in Sickle Cell Disease

Arun S. Shet, MD, from the NIH’s National Heart, Lung, and Blood Institute, and Ted Wun, MD, from UC Davis Comprehensive Cancer Center in...
Advertisement

Current Issue

June 2020, Volume 6, Issue 7

This issue explores COVID-19-associated coagulopathy, features frequently asked questions from oncologists, and more.